Primary Large-Cell Non-Hodgkin's Lymphoma of the Testis: A Retrospective Analysis of Patterns of Failure and Prognostic Factors

2001 ◽  
Vol 2 (2) ◽  
pp. 109-115 ◽  
Author(s):  
John F. Seymour ◽  
Benjamin Solomon ◽  
Max M. Wolf ◽  
E. Henry Janusczewicz ◽  
Andrew Wirth ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Retrospective Analysis ◽  
Hodgkin’S Lymphoma ◽  
Large Cell ◽  
Hodgkin's Lymphoma ◽  
Patterns Of Failure ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Diffuse Large Cell Lymphomas: Identification of Prognostic Factors and Validation of the International Non-Hodgkin’s Lymphoma Prognostic Index

Oncology ◽  
1998 ◽  
Vol 55 (5) ◽  
pp. 405-415 ◽  
Author(s):  
C. Nicolaides ◽  
G. Fountzilas ◽  
N. Zoumbos ◽  
D. Skarlos ◽  
P. Kosmidis ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Hodgkin’S Lymphoma ◽  
Prognostic Index ◽  
Large Cell ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.

1998 ◽  
Vol 16 (10) ◽  
pp. 3246-3256 ◽  
Author(s):  
G L DeNardo ◽  
S J DeNardo ◽  
D S Goldstein ◽  
L A Kroger ◽  
K R Lamborn ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Radiation Dosimetry ◽  
Large Cell ◽  
Maximum Tolerated Dose ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Iodine 131 ◽  
Grade 3 ◽  
Dose Limiting Toxicity

PURPOSE Lym-1, a monoclonal antibody that preferentially targets malignant lymphocytes, has induced remissions in patients with non-Hodgkin's lymphoma (NHL) when labeled with iodine 131 ((131)I). Based on the strategy of fractionating the total dose, this study was designed to define the maximum-tolerated dose (MTD) and efficacy of the first two, of a maximum of four, doses of (131)I-Lym-1 given 4 weeks apart. Additionally, toxicity and radiation dosimetry were assessed. MATERIALS AND METHODS Twenty patients with advanced NHL entered the study a total of 21 times. Thirteen (62%) of the 21 entries had diffuse large-cell histologies. All patients had disease resistant to standard therapy and had received a mean of four chemotherapy regimens. (131)I-Lym-1 was given after Lym-1 and (131)I was escalated in cohorts of patients from 40 to 100 mCi (1.5 to 3.7 GBq)/m2 body surface area. RESULTS Mean radiation dose to the bone marrow from body and blood (131)I was 0.34 (range, 0. 1 6 to 0.63) rad/mCi (0.09 mGy/MBq; range, 0.04 to 0.17 mGy/ MBq). Dose-limiting toxicity was grade 3 to 4 thrombocytopenia with an MTD of 100 mCi/m2 (3.7 GBq/m2) for each of the first two doses of (131)I-Lym-1 given 4 weeks apart. Nonhematologic toxicities did not exceed grade 2 except for one instance of grade 3 hypotension. Ten (71 %) of 14 entries who received at least two doses of (131)I-Lym-1 therapy and 11 (52%) of 21 total entries responded. Seven of the responses were complete, with a mean duration of 14 months. All three entries in the 100 mCi/m2 (3.7 MBq/m2) cohort had complete remissions (CRs). All responders had at least a partial remission (PR) after the first therapy dose of (131)I-Lym-1. CONCLUSION (131)I-Lym-1 induced durable remissions in patients with NHL resistant to chemotherapy and was associated with acceptable toxicity. The nonmyeloablative MTD for each of the first two doses of (131)I-Lym-1 was 100 mCi/m2 (total, 200 mCi/m2) (3.7 GBq/m2; total, 7.4 GBq/m2).

Chemotherapy with MECOP-B for Intermediate-Grade and High-Grade Non-Hodgkin’s Lymphoma in Saudi Arabia: Clinical Results and Analysis of Prognostic Factors

1996 ◽  
Vol 96 (3) ◽  
pp. 126-134
Author(s):  
Ezzeldin M. Ibrahim ◽  
Reem F. Bunyan ◽  
Fatma A. Al-Mulhim ◽  
Arwa A. Al-Nabhan ◽  
Rania E. Ibrahimá
Keyword(s):  
Saudi Arabia ◽  
Prognostic Factors ◽  
Hodgkin’S Lymphoma ◽  
Clinical Results ◽  
Hodgkin's Lymphoma ◽  
High Grade ◽  
Intermediate Grade ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma
Sign in / Sign up

Export Citation Format

Share Document